<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583713</url>
  </required_header>
  <id_info>
    <org_study_id>BLI-800-202</org_study_id>
    <nct_id>NCT00583713</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in
      two groups of patients and one group of healthy controls. The patient groups will be those
      with mild or moderate hepatic impairment or moderate renal disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve for the 24-hour Dosing Interval</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Sulfate Concentration</measure>
    <time_frame>pre-dose to 6 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Colonoscopy</condition>
  <condition>Bowel Preparation</condition>
  <arm_group>
    <arm_group_label>Renal Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild/moderate hepatic impairment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI-800</intervention_name>
    <description>BLI-800 oral solution (two doses)</description>
    <arm_group_label>Renal Group</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Hepatic Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are male or female adults who are:

               -  With Child-Pugh Hepatic Dysfunction Stage A or B, or

               -  With Moderate Renal Disease or

               -  Healthy subjects matched to those who are enrolled in this study

          -  Subjects who are considered to have only clinically non-significant conditions, as
             judged by the Principal Investigator and based on physical examination, laboratory
             profiles, medical history and ECG.

          -  Female subjects who are not surgically sterile (i.e., having had a hysterectomy,
             bilateral oophorectomy or tubal ligation) or who are not at least 2 years naturally
             postmenopausal must agree to use an acceptable form of contraception.

          -  Provide voluntary consent in writing to participate in this study.

        Exclusion Criteria:

          -  Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal
             obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.

          -  Subjects with impaired consciousness that predisposes them to pulmonary aspiration.

          -  Subjects who, in the opinion of the Principal Investigator, have uncontrolled
             clinically significant pre-existing electrolyte disturbances, based on the Screening
             visit laboratory results.

          -  Subjects with present or prior NYHA Functional Classification grade III or IV
             congestive heart failure.

          -  Subjects who are pregnant or lactating, or intending to become pregnant during the
             study.

          -  Subjects of childbearing potential who refuse a pregnancy test.

          -  Subjects who have participated in an investigational clinical, surgical, drug, or
             device study within the past 30 days.

          -  Subjects with a history of allergic or adverse response to any BLI-800 component.

          -  Subjects who donated more than one pint of blood within 30 days prior to the study.

          -  Subjects who donated plasma within 7 days prior to the study.

          -  Subjects who had an abnormal diet or substantial changes in eating habits within 30
             days prior to the start of the study.

          -  Subjects who have had a bowel cleansing procedure within the past month or who have
             taken a laxative within the 5 days (120 hours) prior to dosing or who require a
             laxative every day.

          -  Subjects who, in the opinion of the Investigator, should not be included in the study
             for any reason, including inability to follow study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Pelham, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <results_first_submitted>September 17, 2010</results_first_submitted>
  <results_first_submitted_qc>October 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2010</results_first_posted>
  <disposition_first_submitted>January 22, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 24, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>October 29, 2010</last_update_submitted>
  <last_update_submitted_qc>October 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Russell Pelham, Ph.D.</name_title>
    <organization>Braintree Laboratories, Inc.</organization>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Renal Group</title>
          <description>BLI-800 oral solution in patients with moderate renal impairment</description>
        </group>
        <group group_id="P2">
          <title>Healthy Volunteers</title>
          <description>BLI-800 oral solution in healthy volunteers</description>
        </group>
        <group group_id="P3">
          <title>Hepatic Group</title>
          <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Renal Group</title>
          <description>BLI-800 oral solution in patients with moderate renal impairment</description>
        </group>
        <group group_id="B2">
          <title>Healthy Volunteers</title>
          <description>BLI-800 oral solution in healthy volunteers</description>
        </group>
        <group group_id="B3">
          <title>Hepatic Group</title>
          <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="7.96"/>
                    <measurement group_id="B2" value="49.0" spread="6.93"/>
                    <measurement group_id="B3" value="51.2" spread="5.74"/>
                    <measurement group_id="B4" value="51.3" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax)</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Group</title>
            <description>BLI-800 oral solution in patients with moderate renal impairment</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>BLI-800 oral solution in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Hepatic Group</title>
            <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax)</title>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="717.0" spread="270.84"/>
                    <measurement group_id="O2" value="499.5" spread="165.00"/>
                    <measurement group_id="O3" value="560.2" spread="152.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Sulfate Concentration</title>
        <time_frame>pre-dose to 6 days post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Group</title>
            <description>BLI-800 oral solution in patients with moderate renal impairment</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>BLI-800 oral solution in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Hepatic Group</title>
            <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Sulfate Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.58" spread="40.12"/>
                    <measurement group_id="O2" value="131.20" spread="46.98"/>
                    <measurement group_id="O3" value="86.92" spread="50.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.53" spread="86.28"/>
                    <measurement group_id="O2" value="145.62" spread="111.02"/>
                    <measurement group_id="O3" value="89.83" spread="67.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.98" spread="47.61"/>
                    <measurement group_id="O2" value="134.65" spread="74.72"/>
                    <measurement group_id="O3" value="70.82" spread="83.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Group</title>
            <description>BLI-800 oral solution in patients with moderate renal impairment</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>BLI-800 oral solution in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Hepatic Group</title>
            <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="2.95"/>
                    <measurement group_id="O2" value="16.8" spread="8.16"/>
                    <measurement group_id="O3" value="14.2" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Group</title>
            <description>BLI-800 oral solution in patients with moderate renal impairment</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>BLI-800 oral solution in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Hepatic Group</title>
            <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" spread="9.32"/>
                    <measurement group_id="O2" value="8.51" spread="4.57"/>
                    <measurement group_id="O3" value="5.58" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve for the 24-hour Dosing Interval</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Group</title>
            <description>BLI-800 oral solution in patients with moderate renal impairment</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>BLI-800 oral solution in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Hepatic Group</title>
            <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for the 24-hour Dosing Interval</title>
          <units>µmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12,332.95" spread="4,193.54"/>
                    <measurement group_id="O2" value="8,029.88" spread="3,424.42"/>
                    <measurement group_id="O3" value="10,751.75" spread="2,878.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Rate Constant</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Group</title>
            <description>BLI-800 oral solution in patients with moderate renal impairment</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>BLI-800 oral solution in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Hepatic Group</title>
            <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant</title>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" spread="0.09"/>
                    <measurement group_id="O2" value="0.107" spread="0.06"/>
                    <measurement group_id="O3" value="0.141" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Renal Group</title>
          <description>BLI-800 oral solution in patients with moderate renal impairment</description>
        </group>
        <group group_id="E2">
          <title>Healthy Volunteers</title>
          <description>BLI-800 oral solution in healthy volunteers</description>
        </group>
        <group group_id="E3">
          <title>Hepatic Group</title>
          <description>BLI-800 oral solution in patients with mild/moderate hepatic impairment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Perianal irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal urinalysis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Elevated serum creatinine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Symptomatic hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Russell Pelham, PhD</name_or_title>
      <organization>Braintree Laboratories, Inc.</organization>
      <phone>781-843-2202</phone>
      <email>rpelham@braintreelabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

